01—Abstract
Summary
Summary of the 10-Q filed July 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation's Form 10-Q for the quarter ended June 30, 2024 reports a net loss of $444.6 milliona, or $2.04 per share, for the three months ended June 30, 2024, compared with net income of $203.5 million, or $0.91 per basic share, in the prior-year quarter.
For the six months, the company reported a net loss of $275.1 millionb, or $1.24 per share. The swing was driven primarily by a $679.4 million charge for acquired in-process research and development from the May 30, 2024 acquisition of Escient Pharmaceuticals, Inc., which was expensed as research and development. Total revenues rose to $1,043.8 million in the quarter from $954.6 million, led by product revenues of $906.6 million, with JAKAFI revenues of $706.0 million and OPZELURA revenues of $121.7 million.
Balance sheet and capital allocation changed significantly during the period. Cash and cash equivalents declined to $987.3 millionc at June 30, 2024 from $3.21 billion at December 31, 2023, reflecting a $2.0 billion share repurchase completed in June 2024 (33,325,849 shares at $60.00 per share, including 5,459,183 shares bought from the Baker Entities). Total stockholders' equity fell to $2.997 billion from $5.190 billion.
Net cash used in operating activities was $356.8 milliond for the six months, versus $200.9 million provided in the prior-year period, which the filing attributes primarily to the Escient acquisition and working capital changes. The company also held $462.2 million in marketable securities and $69.9 million in short-term equity investments, and its $500.0 million revolving credit facility was undrawn and was extended to June 2027.
The filing also highlights ongoing risks: a $433.2 million accrued royalty liability tied to a contract dispute with Novartis over U.S. JAKAFI royalties, a $91.1 million accrual related to a lawsuit against CMS over the OPZELURA Medicaid line-extension designation, and the company's reliance on JAKAFI for a significant share of revenue. Management also disclosed a strategic pipeline review in July 2024 that will discontinue several earlier-stage programs.
02—Key points
Key Highlights
- Net loss of $444.6 million ($2.04 per share) in Q2 2024, versus net income of $203.5 million ($0.91 basic per share) in Q2 2023, driven by a $679.4 million expensed IPR&D charge from the Escient acquisition.
- Total revenues increased to $1,043.8 million in Q2 2024 from $954.6 million, with product revenues of $906.6 million and product royalty revenues of $137.2 million.
- OPZELURA revenues were $121.7 million in Q2 2024 versus $80.2 million a year earlier; JAKAFI revenues were $706.0 million versus $682.4 million.
- Completed a $2.0 billion share repurchase in June 2024 at $60.00 per share, reducing shares outstanding to 191,572,449 at June 30, 2024 from 224,286,862 at December 31, 2023.
- Cash and cash equivalents fell to $987.3 million from $3.21 billion at year-end 2023; net cash used in operating activities was $356.8 million for the six months.
- Escient acquisition on May 30, 2024 for $782.5 million cash; the company recognized $679.4 million of in-process R&D expense and $31.5 million of accelerated stock compensation.
- Disclosed a $433.2 million accrued royalty liability to Novartis tied to a contract dispute over U.S. JAKAFI royalties, and a $91.1 million accrual related to the OPZELURA line-extension lawsuit against CMS.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q2 FY2024, Incyte lost $0.43.
- Revenue$1.04B100.0%
- Cost of revenue−$76.6M7.3%
- Gross profit$967.1M92.7%
- Operating costs−$1.45B138.5%
- Operating income−$478.1M45.8%
- Interest, other & tax$33.5M3.2%
- Net income−$444.6M42.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed July 30, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $1.04B$954.61M | +9.3% |
| Cost of Revenue | $76.63M$68.33M | +12.2% |
| Gross Profit | $967.13M$886.28M | +9.1% |
| R&D Expenses | $1.14B$400.75M | +184.1% |
| SG&A Expenses | $305.98M$283.93M | +7.8% |
| Operating Expenses | $1.52B$760.83M | +100.0% |
| Operating Income | -$478.13M$193.78M | −346.7% |
| Net Income | -$444.60M$203.55M | −318.4% |
| EPS (Basic) | $-2.04$0.91 | −324.2% |
| EPS (Diluted) | $-2.04$0.90 | −326.7% |
| Shares Outstanding (Basic) | 218.18M223.25M | −2.3% |
| Shares Outstanding (Diluted) | 218.18M225.65M | −3.3% |
05—Questions
Frequently Asked Questions
Why did Incyte swing from net income to a net loss in the second quarter of 2024?
The primary driver was $679.4 million of acquired in-process research and development expense from the Escient Pharmaceuticals acquisition, which was recognized in full as R&D expense because the assets had no alternative future use. Research and development expense rose to $1,138.4 million in the quarter from $400.8 million, while the company also recorded a $35.5 million...
How much did Incyte spend on its share repurchases, and how did it affect the balance sheet?
Incyte repurchased 33,325,849 shares at $60.00 per share for approximately $2.0 billion in June 2024, comprising a modified Dutch auction tender offer of 27,866,666 shares (about $1.672 billion) and 5,459,183 shares bought from the Baker Entities (about $328.0 million). Total stockholders' equity declined to $2.997 billion from $5.190 billion at December 31, 2023, and the filing notes $24.3 million of associated fees and expenses, including $19.2 million of excise tax expected to be paid in the second quarter of 2025.
What are the main risks flagged in the filing for JAKAFI revenues?
JAKAFI product revenues were $706.0 million in Q2 2024, and the filing states the company depends heavily on JAKAFI. Risks include generic competition (a February 2024 ANDA notice letter challenges patents expiring in 2028), government reimbursement pressure, and a contract dispute with Novartis over U.S. royalties on JAKAFI net sales, for which $433.2 million of accrued royalties was recorded as of June 30, 2024.
What is the status of the Credit Agreement and the company's liquidity position?
The company had no outstanding borrowings under its $500.0 million revolving credit facility at June 30, 2024 and was in compliance with covenants. The June 2024 amendment extended maturity from August 2024 to June 2027. Management stated that cash flow from operations, cash and marketable securities of approximately $1.4 billion, and the revolving facility are expected to be adequate for capital needs for the foreseeable future.
What did Incyte announce about its pipeline in July 2024?
The filing states that in July 2024 the company announced a strategic pipeline review with increased focus on high potential impact programs. It will discontinue further development of both oral small-molecule PD-L1 inhibitors, the LAG-3 monoclonal antibody, the TIM-3 monoclonal antibody and the LAG-3xPD-1 bispecific. The filing also reports positive topline Phase 3 results for retifanlimab in squamous cell anal carcinoma and non-small cell lung cancer.
06—Continue